The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Peptide Drugs for Intestinal Diseases Market Research Report 2025
Synopsis
The global market for Peptide Drugs for Intestinal Diseases was valued at US$ 2460 million in the year 2024 and is projected to reach a revised size of US$ 4651 million by 2031, growing at a CAGR of 9.6% during the forecast period.
Peptide drugs for intestinal diseases are a class of innovative therapeutics based on peptide molecules, primarily used for treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), intestinal infections, and other digestive disorders. These drugs are known for their high specificity and low toxicity, acting by modulating gut immune responses, repairing intestinal barrier function, or regulating neuro-gut signaling pathways. For example, GLP-1 receptor agonists are used to treat metabolic disorders related to gut function, while certain antimicrobial peptides directly inhibit the growth of intestinal pathogens. With advancements in biotechnology, an increasing number of novel peptide drugs are entering clinical trials, offering safer and more effective treatment options for patients with intestinal diseases.
North American market for Peptide Drugs for Intestinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peptide Drugs for Intestinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Peptide Drugs for Intestinal Diseases include AbbVie, Takeda Pharmaceuticals, Salix Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Drugs for Intestinal Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Drugs for Intestinal Diseases.
The Peptide Drugs for Intestinal Diseases market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Drugs for Intestinal Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Drugs for Intestinal Diseases manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AbbVie
Takeda Pharmaceuticals
Salix Pharmaceuticals
Segment by Type
Linaclotide
Plecanatide
Teduglutide
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide Drugs for Intestinal Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide Drugs for Intestinal Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Peptide Drugs for Intestinal Diseases was valued at US$ 2460 million in the year 2024 and is projected to reach a revised size of US$ 4651 million by 2031, growing at a CAGR of 9.6% during the forecast period.
Peptide drugs for intestinal diseases are a class of innovative therapeutics based on peptide molecules, primarily used for treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), intestinal infections, and other digestive disorders. These drugs are known for their high specificity and low toxicity, acting by modulating gut immune responses, repairing intestinal barrier function, or regulating neuro-gut signaling pathways. For example, GLP-1 receptor agonists are used to treat metabolic disorders related to gut function, while certain antimicrobial peptides directly inhibit the growth of intestinal pathogens. With advancements in biotechnology, an increasing number of novel peptide drugs are entering clinical trials, offering safer and more effective treatment options for patients with intestinal diseases.
North American market for Peptide Drugs for Intestinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peptide Drugs for Intestinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Peptide Drugs for Intestinal Diseases include AbbVie, Takeda Pharmaceuticals, Salix Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Drugs for Intestinal Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Drugs for Intestinal Diseases.
The Peptide Drugs for Intestinal Diseases market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Drugs for Intestinal Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Drugs for Intestinal Diseases manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AbbVie
Takeda Pharmaceuticals
Salix Pharmaceuticals
Segment by Type
Linaclotide
Plecanatide
Teduglutide
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide Drugs for Intestinal Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide Drugs for Intestinal Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Peptide Drugs for Intestinal Diseases Market Overview
1.1 Product Definition
1.2 Peptide Drugs for Intestinal Diseases by Type
1.2.1 Global Peptide Drugs for Intestinal Diseases Market Value Comparison by Type (2024 VS 2031)
1.2.2 Linaclotide
1.2.3 Plecanatide
1.2.4 Teduglutide
1.3 Peptide Drugs for Intestinal Diseases by Application
1.3.1 Global Peptide Drugs for Intestinal Diseases Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Peptide Drugs for Intestinal Diseases Market Size Estimates and Forecasts
1.4.1 Global Peptide Drugs for Intestinal Diseases Revenue 2020-2031
1.4.2 Global Peptide Drugs for Intestinal Diseases Sales 2020-2031
1.4.3 Global Peptide Drugs for Intestinal Diseases Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Peptide Drugs for Intestinal Diseases Market Competition by Manufacturers
2.1 Global Peptide Drugs for Intestinal Diseases Sales Market Share by Manufacturers (2020-2025)
2.2 Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Peptide Drugs for Intestinal Diseases Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Peptide Drugs for Intestinal Diseases, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Product Type & Application
2.7 Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Date of Enter into This Industry
2.8 Global Peptide Drugs for Intestinal Diseases Market Competitive Situation and Trends
2.8.1 Global Peptide Drugs for Intestinal Diseases Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Peptide Drugs for Intestinal Diseases Players Market Share by Revenue
2.8.3 Global Peptide Drugs for Intestinal Diseases Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peptide Drugs for Intestinal Diseases Market Scenario by Region
3.1 Global Peptide Drugs for Intestinal Diseases Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Peptide Drugs for Intestinal Diseases Sales by Region: 2020-2031
3.2.1 Global Peptide Drugs for Intestinal Diseases Sales by Region: 2020-2025
3.2.2 Global Peptide Drugs for Intestinal Diseases Sales by Region: 2026-2031
3.3 Global Peptide Drugs for Intestinal Diseases Revenue by Region: 2020-2031
3.3.1 Global Peptide Drugs for Intestinal Diseases Revenue by Region: 2020-2025
3.3.2 Global Peptide Drugs for Intestinal Diseases Revenue by Region: 2026-2031
3.4 North America Peptide Drugs for Intestinal Diseases Market Facts & Figures by Country
3.4.1 North America Peptide Drugs for Intestinal Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Peptide Drugs for Intestinal Diseases Sales by Country (2020-2031)
3.4.3 North America Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peptide Drugs for Intestinal Diseases Market Facts & Figures by Country
3.5.1 Europe Peptide Drugs for Intestinal Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Peptide Drugs for Intestinal Diseases Sales by Country (2020-2031)
3.5.3 Europe Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide Drugs for Intestinal Diseases Market Facts & Figures by Region
3.6.1 Asia Pacific Peptide Drugs for Intestinal Diseases Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Peptide Drugs for Intestinal Diseases Sales by Region (2020-2031)
3.6.3 Asia Pacific Peptide Drugs for Intestinal Diseases Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peptide Drugs for Intestinal Diseases Market Facts & Figures by Country
3.7.1 Latin America Peptide Drugs for Intestinal Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Peptide Drugs for Intestinal Diseases Sales by Country (2020-2031)
3.7.3 Latin America Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peptide Drugs for Intestinal Diseases Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide Drugs for Intestinal Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Peptide Drugs for Intestinal Diseases Sales by Country (2020-2031)
3.8.3 Middle East and Africa Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peptide Drugs for Intestinal Diseases Sales by Type (2020-2031)
4.1.1 Global Peptide Drugs for Intestinal Diseases Sales by Type (2020-2025)
4.1.2 Global Peptide Drugs for Intestinal Diseases Sales by Type (2026-2031)
4.1.3 Global Peptide Drugs for Intestinal Diseases Sales Market Share by Type (2020-2031)
4.2 Global Peptide Drugs for Intestinal Diseases Revenue by Type (2020-2031)
4.2.1 Global Peptide Drugs for Intestinal Diseases Revenue by Type (2020-2025)
4.2.2 Global Peptide Drugs for Intestinal Diseases Revenue by Type (2026-2031)
4.2.3 Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Type (2020-2031)
4.3 Global Peptide Drugs for Intestinal Diseases Price by Type (2020-2031)
5 Segment by Application
5.1 Global Peptide Drugs for Intestinal Diseases Sales by Application (2020-2031)
5.1.1 Global Peptide Drugs for Intestinal Diseases Sales by Application (2020-2025)
5.1.2 Global Peptide Drugs for Intestinal Diseases Sales by Application (2026-2031)
5.1.3 Global Peptide Drugs for Intestinal Diseases Sales Market Share by Application (2020-2031)
5.2 Global Peptide Drugs for Intestinal Diseases Revenue by Application (2020-2031)
5.2.1 Global Peptide Drugs for Intestinal Diseases Revenue by Application (2020-2025)
5.2.2 Global Peptide Drugs for Intestinal Diseases Revenue by Application (2026-2031)
5.2.3 Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Application (2020-2031)
5.3 Global Peptide Drugs for Intestinal Diseases Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Peptide Drugs for Intestinal Diseases Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Peptide Drugs for Intestinal Diseases Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Takeda Pharmaceuticals
6.2.1 Takeda Pharmaceuticals Company Information
6.2.2 Takeda Pharmaceuticals Description and Business Overview
6.2.3 Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio
6.2.5 Takeda Pharmaceuticals Recent Developments/Updates
6.3 Salix Pharmaceuticals
6.3.1 Salix Pharmaceuticals Company Information
6.3.2 Salix Pharmaceuticals Description and Business Overview
6.3.3 Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio
6.3.5 Salix Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide Drugs for Intestinal Diseases Industry Chain Analysis
7.2 Peptide Drugs for Intestinal Diseases Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide Drugs for Intestinal Diseases Production Mode & Process Analysis
7.4 Peptide Drugs for Intestinal Diseases Sales and Marketing
7.4.1 Peptide Drugs for Intestinal Diseases Sales Channels
7.4.2 Peptide Drugs for Intestinal Diseases Distributors
7.5 Peptide Drugs for Intestinal Diseases Customer Analysis
8 Peptide Drugs for Intestinal Diseases Market Dynamics
8.1 Peptide Drugs for Intestinal Diseases Industry Trends
8.2 Peptide Drugs for Intestinal Diseases Market Drivers
8.3 Peptide Drugs for Intestinal Diseases Market Challenges
8.4 Peptide Drugs for Intestinal Diseases Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Peptide Drugs for Intestinal Diseases Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Peptide Drugs for Intestinal Diseases Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Peptide Drugs for Intestinal Diseases Market Competitive Situation by Manufacturers in 2024
Table 4. Global Peptide Drugs for Intestinal Diseases Sales (kg) of Key Manufacturers (2020-2025)
Table 5. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Peptide Drugs for Intestinal Diseases Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Peptide Drugs for Intestinal Diseases Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Peptide Drugs for Intestinal Diseases Average Price (US$/g) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Peptide Drugs for Intestinal Diseases, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Product Type & Application
Table 12. Global Key Manufacturers of Peptide Drugs for Intestinal Diseases, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide Drugs for Intestinal Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Drugs for Intestinal Diseases as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Peptide Drugs for Intestinal Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Peptide Drugs for Intestinal Diseases Sales by Region (2020-2025) & (kg)
Table 18. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Region (2020-2025)
Table 19. Global Peptide Drugs for Intestinal Diseases Sales by Region (2026-2031) & (kg)
Table 20. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Region (2026-2031)
Table 21. Global Peptide Drugs for Intestinal Diseases Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Region (2020-2025)
Table 23. Global Peptide Drugs for Intestinal Diseases Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Region (2026-2031)
Table 25. North America Peptide Drugs for Intestinal Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Peptide Drugs for Intestinal Diseases Sales by Country (2020-2025) & (kg)
Table 27. North America Peptide Drugs for Intestinal Diseases Sales by Country (2026-2031) & (kg)
Table 28. North America Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Peptide Drugs for Intestinal Diseases Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Peptide Drugs for Intestinal Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Peptide Drugs for Intestinal Diseases Sales by Country (2020-2025) & (kg)
Table 32. Europe Peptide Drugs for Intestinal Diseases Sales by Country (2026-2031) & (kg)
Table 33. Europe Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Peptide Drugs for Intestinal Diseases Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Peptide Drugs for Intestinal Diseases Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Peptide Drugs for Intestinal Diseases Sales by Region (2020-2025) & (kg)
Table 37. Asia Pacific Peptide Drugs for Intestinal Diseases Sales by Region (2026-2031) & (kg)
Table 38. Asia Pacific Peptide Drugs for Intestinal Diseases Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Peptide Drugs for Intestinal Diseases Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Peptide Drugs for Intestinal Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Peptide Drugs for Intestinal Diseases Sales by Country (2020-2025) & (kg)
Table 42. Latin America Peptide Drugs for Intestinal Diseases Sales by Country (2026-2031) & (kg)
Table 43. Latin America Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Peptide Drugs for Intestinal Diseases Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Peptide Drugs for Intestinal Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Peptide Drugs for Intestinal Diseases Sales by Country (2020-2025) & (kg)
Table 47. Middle East and Africa Peptide Drugs for Intestinal Diseases Sales by Country (2026-2031) & (kg)
Table 48. Middle East and Africa Peptide Drugs for Intestinal Diseases Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Peptide Drugs for Intestinal Diseases Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Peptide Drugs for Intestinal Diseases Sales (kg) by Type (2020-2025)
Table 51. Global Peptide Drugs for Intestinal Diseases Sales (kg) by Type (2026-2031)
Table 52. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Type (2020-2025)
Table 53. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Type (2026-2031)
Table 54. Global Peptide Drugs for Intestinal Diseases Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Peptide Drugs for Intestinal Diseases Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Type (2020-2025)
Table 57. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Type (2026-2031)
Table 58. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Type (2020-2025)
Table 59. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Type (2026-2031)
Table 60. Global Peptide Drugs for Intestinal Diseases Sales (kg) by Application (2020-2025)
Table 61. Global Peptide Drugs for Intestinal Diseases Sales (kg) by Application (2026-2031)
Table 62. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Application (2020-2025)
Table 63. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Application (2026-2031)
Table 64. Global Peptide Drugs for Intestinal Diseases Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Peptide Drugs for Intestinal Diseases Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Application (2020-2025)
Table 67. Global Peptide Drugs for Intestinal Diseases Revenue Market Share by Application (2026-2031)
Table 68. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Application (2020-2025)
Table 69. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Application (2026-2031)
Table 70. AbbVie Company Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Peptide Drugs for Intestinal Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 73. AbbVie Peptide Drugs for Intestinal Diseases Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Takeda Pharmaceuticals Company Information
Table 76. Takeda Pharmaceuticals Description and Business Overview
Table 77. Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 78. Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Product
Table 79. Takeda Pharmaceuticals Recent Developments/Updates
Table 80. Salix Pharmaceuticals Company Information
Table 81. Salix Pharmaceuticals Description and Business Overview
Table 82. Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 83. Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Product
Table 84. Salix Pharmaceuticals Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Peptide Drugs for Intestinal Diseases Distributors List
Table 88. Peptide Drugs for Intestinal Diseases Customers List
Table 89. Peptide Drugs for Intestinal Diseases Market Trends
Table 90. Peptide Drugs for Intestinal Diseases Market Drivers
Table 91. Peptide Drugs for Intestinal Diseases Market Challenges
Table 92. Peptide Drugs for Intestinal Diseases Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Peptide Drugs for Intestinal Diseases
Figure 2. Global Peptide Drugs for Intestinal Diseases Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peptide Drugs for Intestinal Diseases Market Share by Type: 2024 & 2031
Figure 4. Linaclotide Product Picture
Figure 5. Plecanatide Product Picture
Figure 6. Teduglutide Product Picture
Figure 7. Global Peptide Drugs for Intestinal Diseases Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Peptide Drugs for Intestinal Diseases Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Peptide Drugs for Intestinal Diseases Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Peptide Drugs for Intestinal Diseases Market Size (2020-2031) & (US$ Million)
Figure 14. Global Peptide Drugs for Intestinal Diseases Sales (2020-2031) & (kg)
Figure 15. Global Peptide Drugs for Intestinal Diseases Average Price (US$/g) & (2020-2031)
Figure 16. Peptide Drugs for Intestinal Diseases Report Years Considered
Figure 17. Peptide Drugs for Intestinal Diseases Sales Share by Manufacturers in 2024
Figure 18. Global Peptide Drugs for Intestinal Diseases Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Peptide Drugs for Intestinal Diseases Players: Market Share by Revenue in Peptide Drugs for Intestinal Diseases in 2024
Figure 20. Peptide Drugs for Intestinal Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Peptide Drugs for Intestinal Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2020-2031)
Figure 23. North America Peptide Drugs for Intestinal Diseases Revenue Market Share by Country (2020-2031)
Figure 24. United States Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2020-2031)
Figure 27. Europe Peptide Drugs for Intestinal Diseases Revenue Market Share by Country (2020-2031)
Figure 28. Germany Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Peptide Drugs for Intestinal Diseases Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Peptide Drugs for Intestinal Diseases Revenue Market Share by Region (2020-2031)
Figure 35. China Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2020-2031)
Figure 43. Latin America Peptide Drugs for Intestinal Diseases Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Colombia Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Peptide Drugs for Intestinal Diseases Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Peptide Drugs for Intestinal Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Peptide Drugs for Intestinal Diseases by Type (2020-2031)
Figure 54. Global Revenue Market Share of Peptide Drugs for Intestinal Diseases by Type (2020-2031)
Figure 55. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Type (2020-2031)
Figure 56. Global Sales Market Share of Peptide Drugs for Intestinal Diseases by Application (2020-2031)
Figure 57. Global Revenue Market Share of Peptide Drugs for Intestinal Diseases by Application (2020-2031)
Figure 58. Global Peptide Drugs for Intestinal Diseases Price (US$/g) by Application (2020-2031)
Figure 59. Peptide Drugs for Intestinal Diseases Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
